There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines Inc (FIXX) and Taiwan Liposome Company Ltd (TLC) with bullish sentiments.
Homology Medicines Inc (FIXX)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Homology Medicines Inc today and set a price target of $36. The company’s shares closed last Monday at $19.57.
Chattopadhyay noted:
“Our $36 price target is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF, which is based on: beta of 1.11, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.5%, and tax rate of 15% beginning in FY 2028. Three programs contribute to 100% of our target, including: (1) gene therapy for adult patients with classic PKU, HMI-102 represents 66%; (2) HMI-103, a genome editing program for pediatric PKU contributes about 23%; and (3) HMI-202, an IV gene therapy construct for a one-and-done option for late onset infantile metachromatic leukodystrophy forms the remainder.”
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -7.2% and a 38.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Homology Medicines Inc is a Strong Buy with an average price target of $34.33, which is a 63.7% upside from current levels. In a report issued on September 9, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Taiwan Liposome Company Ltd (TLC)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on Taiwan Liposome Company Ltd, with a price target of $10. The company’s shares closed last Monday at $5.01, close to its 52-week low of $4.99.
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 8.6% and a 54.7% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Taiwan Liposome Company Ltd is a Moderate Buy with an average price target of $10.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
